Promoters and FIIs increased stake: This small-cap pharma company targeted Rs 750 crore revenue!
The company plans to launch several new products in the domestic and export markets in Q3 and Q4 of FY24.
The company is ranked among a very few companies to achieve a profit growth every single year from FY13 to FY23. It is among only 16 companies out of 4,200 plus listed companies in the Indian stock exchange to do so as per the analysis of Morningstar.
But the numbers don't stop there. Cash and cash equivalents have tripled, catapulting from Rs. 5.05 crore to a staggering Rs. 15.20 crore. The company's ability to maintain a net debt-free status while experiencing robust growth is a testament to their financial prudence.
Financial Highlights
The name of the company is Lincoln Pharmaceuticals Ltd and its management is confident of maintaining the company's growth momentum in the coming quarters, driven by new product launches, improved operational efficiency, and higher-margin products. The company is targeting a revenue of Rs. 750 crore in FY26.
Key Growth Drivers
New product launches: Lincoln Pharma plans to launch several new products in the domestic and export markets in Q3 and Q4 of FY24. This is expected to boost the company's revenue growth.
Improved operational efficiency: The company is focused on improving its operational efficiency through various initiatives such as cost optimization and capacity utilization.
Higher-margin products: Lincoln Pharma is gradually increasing its focus on higher-margin products such as chronic and lifestyle products.
Other Positive Developments
FII stake increase: Foreign Institutional Investors (FIIs) have increased their stake in Lincoln Pharma from 0.63 per cent in September 2022 to 2.59 per cent in September 2023.
Promoter holding increase: The promoter holding in Lincoln Pharma has also increased from 44.09 per cent in September 2022 to 50.53 per cent in September 2023.
TGA and EU GMP approvals: Lincoln Pharma has recently received TGA and EU GMP approvals for its Cephalosporin plant. This will enable the company to export its products to new markets and boost its revenue growth.
Disclaimer: The article is for informational purposes only and not investment advice.
DSIJ’s 'Tiny Treasure' service recommends researched Small-Cap stocks with Inherent Growth Potential. If this interests you, do download the service details here.